Skip to content

I2BIO-HD. Innovative Imaging and cognitive BIOmarkers to predict Huntington’s Disease progression

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516022-63-00
Acronym
APHP210360
Enrollment
100
Registered
2024-11-06
Start date
2024-03-21
Completion date
Unknown
Last updated
2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with symptomatic and pre-symptomatic Huntington's disease

Brief summary

The primary endpoint will be effect size, assessed by the standardized mean difference (Cohen's d) for each biomarker between the values measured initially and their assessment at 2-year follow-up.

Detailed description

Analysis of patient profiles and progression trajectories, taking into account all available data at D0, M1, M1 bis, M12, M24 and M24 bis, will be based on socio-demographic characteristics, as well as initial clinical and paraclinical scores and their evolution over time. Clustering analyses will use statistical validation indices to determine the optimal number of clusters and provide information on cluster quality., Identification of the best biomarkers predicting an unfavorable disease course will be carried out using conventional regression and machine learning methods. Discrimination and calibration performances will be systematically evaluated and compared for each of the models constructed.

Interventions

DRUG[18F]MNI-659

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The primary endpoint will be effect size, assessed by the standardized mean difference (Cohen's d) for each biomarker between the values measured initially and their assessment at 2-year follow-up.

Secondary

MeasureTime frame
Analysis of patient profiles and progression trajectories, taking into account all available data at D0, M1, M1 bis, M12, M24 and M24 bis, will be based on socio-demographic characteristics, as well as initial clinical and paraclinical scores and their evolution over time. Clustering analyses will use statistical validation indices to determine the optimal number of clusters and provide information on cluster quality., Identification of the best biomarkers predicting an unfavorable disease course will be carried out using conventional regression and machine learning methods. Discrimination and calibration performances will be systematically evaluated and compared for each of the models constructed.

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026